Compare · JNJ vs RMTI
JNJ vs RMTI
Side-by-side comparison of Johnson & Johnson (JNJ) and Rockwell Medical Inc. (RMTI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and RMTI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 25195.8x RMTI ($24.2M).
- Over the past year, JNJ is up 53.9% and RMTI is down 45.2% - JNJ leads by 99.1 points.
- RMTI has been more active in the news (13 items in the past 4 weeks vs 7 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 3 for RMTI).
- Company
- Johnson & Johnson
- Rockwell Medical Inc.
- Price
- $253.01+1.39%
- $6.17+6.93%
- Market cap
- $609.12B
- $24.2M
- 1M return
- +7.55%
- -9.02%
- 1Y return
- +53.90%
- -45.16%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- News (4w)
- 7
- 13
- Recent ratings
- 25
- 3
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Rockwell Medical Inc.
Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson
Latest RMTI
- Rockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
- Director Dawson Joseph H was granted 9,633 shares, increasing direct ownership by 385% to 12,133 units (SEC Form 4)
- Director Nissenson Allen was granted 9,633 shares, increasing direct ownership by 68% to 23,892 units (SEC Form 4)
- Director Lau Joan was granted 9,633 shares, increasing direct ownership by 85% to 20,944 units (SEC Form 4)
- Director Radie Robert S was granted 9,633 shares, increasing direct ownership by 67% to 23,985 units (SEC Form 4)
- Director Cooper John G was granted 9,633 shares, increasing direct ownership by 69% to 23,670 units (SEC Form 4)
- SVP and CCO Chole Timothy was granted 15,000 shares, increasing direct ownership by 122% to 27,285 units (SEC Form 4)
- Chief Operating Officer Hunter Heather was granted 15,000 shares, increasing direct ownership by 115% to 28,007 units (SEC Form 4)
- EVP, CLO & Secretary Timmins Megan C. was granted 15,000 shares, increasing direct ownership by 92% to 31,240 units (SEC Form 4)
- SVP and CFO Neri Jesse was granted 15,000 shares, increasing direct ownership by 123% to 27,239 units (SEC Form 4)